Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815295 · ClinicalTrials.gov registry record · Phase 1
Study of Sorafenib/Cetuximab in Head and Neck Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00815295 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 31 participants.
The verdict
NCT00815295, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Interventions
- DRUG Cetuximab
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815295
The ClinicalTrials.gov registry entry for NCT00815295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT00815295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815295 about?
NCT00815295 is a clinical study titled "Study of Sorafenib/Cetuximab in Head and Neck Cancer". In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
What is the current status of trial NCT00815295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2008-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00815295?
The interventions under investigation include: Cetuximab (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00815295?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.